LR-5182

Source: Wikipedia, the free encyclopedia.
LR-5182
Clinical data
Other names(cis)-LR-5182, (cis)-LR-5182 hydrochloride
Identifiers
  • 1-[(2R,3S)-3-(3,4-dichlorophenyl)-2-bicyclo[2.2.2]octanyl]-N,N-dimethylmethanamine
JSmol)
  • CN(C)C[C@@H]1C2CCC(CC2)[C@@H]1c3ccc(Cl)c(Cl)c3

  • HCl: [Cl-].C[NH+](C)C[C@@H]1C2CCC(CC2)[C@@H]1c3ccc(Cl)c(Cl)c3
  • InChI=1S/C17H23Cl2N/c1-20(2)10-14-11-3-5-12(6-4-11)17(14)13-7-8-15(18)16(19)9-13/h7-9,11-12,14,17H,3-6,10H2,1-2H3/t11?,12?,14-,17-/m1/s1
  • Key:JOQQHMGSIKNGAF-HLFYOVGASA-N

  • HCl: InChI=1S/C17H23Cl2N.ClH/c1-20(2)10-14-11-3-5-12(6-4-11)17(14)13-7-8-15(18)16(19)9-13;/h7-9,11-12,14,17H,3-6,10H2,1-2H3;1H/t11?,12?,14-,17-;/m1./s1
  • Key:CWRRQXXGIKGNJA-PQTJMFGHSA-N
  (verify)

LR-5182 is a

fencamfamine.[1][2][3] It was developed by the pharmaceutical company Eli Lilly in the 1970s, and researched for potential use as an antidepressant, although never marketed. LR-5182 has two stereoisomers, both of which are active, although one isomer blocks reuptake of only dopamine and noradrenaline, while the other blocks reuptake of serotonin as well.[4]

While LR-5182 itself never proceeded beyond initial animal studies, discovery of monoamine reuptake inhibition activity and stimulant effects in drugs of this type has subsequently led to the development of many other stimulant drugs of related chemical structure, primarily developed as potential antidepressants,[5] or as substitute drugs for the treatment of cocaine abuse.[6][7]

References